Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights

Abstract EN

Metastatic gastric cancer is still a disease with a poor prognosis.

Recently, different novel agents (e.g., apatinib, nivolumab, TAS-102) have demonstrated a survival advantage compared with placebo for patients with heavily pretreated metastatic gastric cancer.

Although the possible availability of active agents may be a desirable option in a very poor therapeutic scenario, clinical data from the recent studies with these drugs raise yet controversial issues.

The purpose of this review is to briefly summarize the results of these novel drugs focusing on the limitations that bring some shadows on their positive therapeutic results.